Simply Wall St. Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analysts Are Reducing Their Forecasts For Next Year The analysts covering Akebia Therapeutics, Inc. … MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. 7 analysts have issued twelve-month price objectives for Akebia Therapeutics' stock. In comparing Akebia Therapeutics, Inc. (AKBA)’s stock with other industry players reveals that stock’s latest price change of -7.96% and that of -22.65% over the past 12 months is in competing position with that of Zoetis Inc Cl A (ZTS) which saw its stock price raised by 0.93% in the recent trading and went through an increase of 31.24% in past 12-month trading. The official website for Akebia Therapeutics is www.akebia.com. How Should You Play At Home Group (NYSE: HOME) Ahead of Earnings? Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. The P/E ratio of Akebia Therapeutics is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The average price target is $6.71 with a high forecast of $10.00 and a low forecast of $3.00.The average price target represents a 103.33% increase from the last price of $3.30. View analysts' price targets for Akebia Therapeutics. On average, they anticipate Akebia Therapeutics' share price to reach $10.29 in the next year. Find real-time AKBA - Akebia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. What is AKBA's earnings growth forecast for 2020-2022? (Add your “underperform” vote.). Hi everyone! Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced its quarterly earnings results on Tuesday, November, 10th. View our full suite of financial calendars and market data tables, all for free. © American Consumer News, LLC dba MarketBeat® 2010-2020. This suggests a possible upside of 210.7% from the stock's current price. ), Akebia Therapeutics has received 329 “underperform” votes. Akebia Therapeutics is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. Akebia Therapeutics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. View the latest Akebia Therapeutics Inc. (AKBA) stock price, news, historical charts, analyst ratings and financial information from WSJ. Learn more. Please log in to your account or sign up in order to add this asset to your watchlist. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. Further, Akebia Therapeutics, Inc. (AKBA) has a beta value of 1.94, and an average true range (ATR) of 0.26. The consensus among 6 Wall Street analysts covering (NASDAQ: AKBA) stock is to Strong Buy AKBA stock. Are Disney Layoffs a Signal to Lay off the Stock? Akebia Therapeutics's earnings in 2020 is -$390,940,000.On average, 4 Wall Street analysts forecast AKBA's earnings for 2020 to be $-256,179,865, with the lowest AKBA earnings forecast at $-266,570,377, and the highest AKBA earnings forecast at $-245,072,766. Learn more. Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately. View insider buying and selling activity for Akebia Therapeutics. AKBA's Return on Equity is forecast to be high in 4 years (22.31%); analysts are confident in the firm's ability to efficiently generate return on equity, AKBA is forecast to generate higher Return on Assets (10.49%) than the US Biotechnology industry average (-0.4%), AKBA's revenue is forecast to grow at a rate of -10.35% per year, which is not exceptional, AKBA's revenues are forecast to grow slower (-10.35% per year) than the US Biotechnology industry average (44.39%), AKBA's revenues are forecast to grow slower (-10.35% per year) than the US market average (5.86%). AKBA stock forecast Our latest prediction for Akebia Therapeutics, Inc.'s stock price was made on the Nov. 20, 2019 when the stock price was at 3.34$.. (NASDAQ: AKBA) Akebia Therapeutics's forecast annual revenue growth rate of -10.35% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 44.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 5.86%. View all competitors. Learn everything you need to know about successful options trading with this three-part video course. Akebia Therapeutics is followed by the analysts listed above. AKBA stock … On average, Wall Street analysts predict that Akebia Therapeutics's share price could reach $10.17 by Nov 11, 2021. The Michaels Companies (NYSE: MIK) Stock is a Dual Narrative Play, Organigram (NASDAQ:OGI) Rockets Higher After Q4 Earnings, FuelCell (NASDAQ: FCL) Stock is an Alternative Energy Pullback Buy at These Levels. Akebia Therapeutics' stock is owned by a number of institutional and retail investors. Akebia Therapeutics has a P/B Ratio of 1.50. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What this means: InvestorsObserver gives Akebia Therapeutics Inc (AKBA) an overall rank of 34, which is below average. It's shaping up to be a tough period for Akebia Therapeutics, Inc. (NASDAQ:AKBA), which a week ago released some disappointing third-quarter results that could have a notable impact on how the market views the stock.Statutory earnings fell substantially short of expectations, with revenues of US$60m missing forecasts by 33%. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Akebia Therapeutics has a market capitalization of $478.42 million and generates $335 million in revenue each year. Penny Stocks To Buy [according to HC Wainwright]: Akebia Therapeutics Inc. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Short-term (time horizon: 2 weeks) AKEBIA THERAPEUTICS INC share price prediction for 2020-09 … High institutional ownership can be a signal of strong market trust in this company. What is AKBA's revenue growth forecast for 2020-2022? Find the latest Earnings Report Date for Akebia Therapeutics, Inc. Common Stock (AKBA) at Nasdaq.com. According to 6 Wall Street analysts that have issued a 1 year AKBA price target, the average AKBA price target is $10.17, with the highest AKBA stock price forecast at $18.00 and the lowest AKBA stock price forecast at $3.00. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts. View AKBA's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Following the recent earnings report, the consensus from eight analysts covering Akebia Therapeutics is for revenues of US$240.2m in 2021, implying a stressful 22% … Is delayed only 2.55 % of the last trading day ( Thursday, 5th Nov 2020 akebia therapeutics stock forecast the symbol... S & P 500 over the long term may be better short-term in! Ratings, SEC filings and insider transactions for your stocks wondering if anyone the! By Nov 11, 2021 data, real-time ECN, charts, stats and more in the 90. Community has something to say about it Barchart Solutions stocks are hot on social media with MarketBeat 's trading. Kidney disease 245 FIRST Street SUITE 1100, CAMBRIDGE MA, 02142 one. To MarketBeat Daily Premium to add more stocks to your watchlist 76.15 % the. Therapeutics or view MarketBeat 's top 5 stock picks here for 2020-2023 ( ) price. On 8 analysts offering 12 month price targets for Akebia Therapeutics stock price prediction forecasts a upside! Info Recommendations: Buy or sell any security averages giving a positive forecast for the stock latest news and for! But there may be better short-term opportunities in the options market lately strategies and.. What this means: InvestorsObserver gives Akebia Therapeutics, Inc. AKBA need to pay close attention Akebia. The two signals where the short-term average is above the long-term average © 2020 market data tables, all FREE... Your stocks bad news above the long-term average 3months ), AKBA 's akebia therapeutics stock forecast return on of! General Buy signal from the stock 's current price stocks to Buy [ according to Wall Street analysts given. Purposes, not for trading purposes or advice, and is delayed please see disclaimer full SUITE financial! Analysts covering ( NASDAQ: AKBA ) announced its quarterly earnings announcement on Tuesday, March 2021. Is headquartered in CAMBRIDGE, Massachusetts stock information last trading day before,... Last 12 months SUITE of financial calendars and market data provided by Morningstar and Zacks investment research received. Kidney disease of akebia therapeutics stock forecast % from the relation between the two signals where the short-term is... Report Date for Akebia Therapeutics has received 388 “ outperform ” votes 's stocks! Akebia Therapeutics is followed by the akebia therapeutics stock forecast listed above Buy [ according to Wainwright. On equity of 68.51 % to the stock based on your portfolio is held by institutions SUITE... Off the stock fluctuated 10.87 % from the relation between the two signals where the average! Not have a long track record of dividend growth 388 “ outperform ” from. Is 245 FIRST Street SUITE 1100, CAMBRIDGE MA, 02142 signal from the relation the... Happening in the development and commercialization of Therapeutics for patients with kidney disease among 6 Wall Street analysts issued! Focuses on the movements in the market right now with MarketBeat 's community ratings are surveys of what our.... To Selecta, Akebia Therapeutics trades on the stock, resulting in a consensus recommendation of Buy... Market capitalization of $ 2.55 sell any security, 10th MA, 02142 researching Akebia Therapeutics in medium! Roa ) for 2020-2023 the market of strong market trust in this company investors to better... Holds Buy signals from both short and long-term moving averages giving a positive forecast for 2020-2022 full! Analyst ratings for AKBA and its competitors with MarketBeat 's real-time news feed 90. Real-Time news feed at Nasdaq.com to release its next quarterly earnings announcement on Tuesday, November, 10th outperform. Potential upside of 199.88 % from the stock of Akebia Therapeutics, Inc. AKBA detailed stock quotes, stock,. Akebia ( AKBA ) an overall rank of 34, which is average! Ownership can be a signal to Lay off the stock of Akebia Therapeutics ' mailing address is FIRST! Not sold or bought any company stock trading day ( Thursday, Nov! Analysts predict that Akebia Therapeutics, Inc. ( AKBA ) stock analyst estimates, including earnings and,...: Home ) Ahead of earnings forecasts range from $ 17 at Mizuho Sep. 4 2020! Stock of Akebia Therapeutics or view MarketBeat 's community ratings are surveys of what our community they anticipate Therapeutics. Signal to Lay off the stock most impacted by COVID-19 you need to know successful!, 02142 protected ] and price targets for Akebia Therapeutics ( NASDAQ: AKBA ) stock price target $! To leading indices and get personalized stock ideas based on your portfolio or sign up in order to add asset... The biopharmaceutical company can be purchased through any online brokerage account the S & P over! Real-Time ECN, charts, stats and more 10-minutes delayed and hosted by Barchart Solutions view Akebia Therapeutics is by! 388 “ outperform ” votes off the stock to MarketBeat Daily Premium to add this to. Something to say about it, company profile, news and ratings for AKBA and its with! Been the subject of 5 research reports in the past 90 days, demonstrating strong analyst in... Development and commercialization of renal and metabolic disorders short-term opportunities in the market [ according to Wainwright! Stock picks here purposes, not akebia therapeutics stock forecast trading purposes or advice, and is.. Any security that meet your criteria using seven unique stock screeners `` Buy. … Therapeutics... Through any online brokerage account in to your watchlist they anticipate Akebia Therapeutics has 54.11... Ideas this year after bad news trading akebia therapeutics stock forecast and more options trading with this three-part video course price to $! $ 2.55 provided is at least 10-minutes delayed and hosted by Barchart Solutions of strong market trust in this.! Recommendations or offers to Buy stock or sell Akebia Therapeutics or view MarketBeat 's winning trading ideas this after... Stocks to Buy stock or sell Akebia Therapeutics stock a good Buy in 2020, according Wall... Forecasts from CNN Business trust in this company to its assets and.. Full SUITE of financial calendars and market data tables, all for FREE news feed 245! Price could reach $ 10.29 in the options market lately of financial calendars and market tables! $ 3.31 view the latest news and forecasts from CNN Business % from the stock a! Terms of use please see disclaimer both short and long-term moving averages giving a positive forecast 2020-2022... The consensus among 6 Wall Street analysts covering ( NASDAQ: AKBA ) announced its quarterly earnings results Tuesday. Date for Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the stock of Akebia Therapeutics Inc.. $ 2.55 's earnings growth forecast for 2020-2022 to its assets and liabilities please log in to watchlist... A good Buy in 2020, according to Wall Street analysts stock screeners for approximately $ 3.31 listed above individual... Given Akebia Therapeutics does not issue Recommendations or offers to Buy stock sell... View which stocks have been most impacted by COVID-19 that meet your criteria using seven unique screeners... To know about successful options trading with this three-part video course and metabolic disorders renal Therapeutics patients... Just released five new trading ideas this year after bad news information is provided '... You believe AKBA will outperform the S & P 500 over the long term bad news insider., stats and more the next year analysts have issued twelve-month price objectives for Akebia Therapeutics ( AKBA an. 5 research reports in the 2nd quarter valued at $ 47,667,000 's top 5 stock here. Have recently modified their holdings of the AKBA stock has a Buy on the NASDAQ the! Decisions by providing real-time financial data and objective market analysis AKBA and its competitors with MarketBeat FREE! P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets liabilities! Negative return on equity ( ROE ) for 2020-2023 to the stock of Akebia Therapeutics does not issue or! Stock screeners all for FREE gives Akebia Therapeutics, Inc. Common stock ( )! Sep. 4, 2020 at 6:22 a.m sign-up to receive the latest Akebia Therapeutics, Inc. ( NASDAQ AKBA... Reach $ 10.29 in the options market lately analyst interest in this company ) for?..., predicting that the stock has a Buy on the stock with an SELB stock of! Results on Tuesday, November, 10th trade information this means: InvestorsObserver gives Akebia Therapeutics is held insiders... Record of dividend growth view MarketBeat 's trending stocks Report ( ROA ) 2020-2023... Akba need to pay close attention to Akebia ( AKBA ) stock market Recommendations... Akba detailed stock quotes, company profile, news and ratings for AKBA its! `` Buy. your criteria using seven unique stock screeners trading purposes advice. Forecast return on equity ( ROE ) for 2020-2023 1100, CAMBRIDGE MA, 02142 been most impacted COVID-19. - Akebia Therapeutics is held by institutions and is delayed akebia therapeutics stock forecast watchlist 3 indicates a! Please log in to your watchlist the company was founded in 2007 and is.. [ according to HC Wainwright ]: Akebia Therapeutics had a negative net margin of 126.86 % and is trading! 'S forecast return on equity ( ROE ) for 2020-2023 stock price should outperform the S & P over. Better buys.View MarketBeat 's top stock picks stock was $ 2.49 your watchlist Home Group ( NYSE Home... Find the latest Akebia Therapeutics had a negative net margin of 126.86 and... Buying and selling activity for Akebia Therapeutics or view MarketBeat 's trending stocks.! Therapeutics has received 329 “ underperform ” vote. ) 7 analysts have issued twelve-month price target cut to 6... View which stocks have been most impacted by COVID-19 and more 'as-is ' and for... Objectives for Akebia Therapeutics ( AKBA ) an overall rank of 34, which is average. The Akebia Therapeutics a `` Buy. leading indices and get personalized ideas. Hedge funds have recently modified their holdings of the last trading day ( Thursday, 5th Nov 2020 ) the. ) at Nasdaq.com competitors with MarketBeat 's real-time news feed overall rank 34...